Key Takeaways
- Mixed quarter, volume up but price down: Significant volume growth was partially offset by price drops, leaving top-line growth modest; EBITDA margin has stabilized around 20-21% but price pressure persists.
- Oversupply in base amines is structural, not cyclical: Methylamine and ethylamine markets face significant overcapacity built for the long term, with new capacity still entering; management expects this situation to continue through FY26 and likely longer.
- Anti-dumping duty on acetonitrile is a near-term catalyst, but not yet in hand: DGTR has recommended the duty and management expects impact in the second part of Q2 FY26, but Ministry of Finance approval is still pending within a 90-100 day window.
- Dahej CAPEX on track for year-end mechanical completion: New specialty chemical products will launch post mechanical completion around December 2025 or January 2026, with financial impact showing up in the next financial year.
- What to watch next quarter: Whether the Ministry of Finance approves the acetonitrile anti-dumping duty, any sign of demand absorption easing the base amine oversupply, and progress on the Dahej project timeline.
Demand & Volume
- Volume growth intact despite soft Q4: The company is achieving double-digit volume growth and expects 10-15% volume growth to continue next year; Q4 demand was slightly lower due to temporary customer-specific issues in specialty chemicals, not macro weakness, and those customers are now back to normal.
- Revenue growth broad-based: Growth is similar across all three segments: amines, amine derivatives, and specialty products; the company is growing across all segments.
- India opportunity underpins cautious optimism: Management struck a cautiously optimistic tone, noting that customers are growing, the market is not going anywhere, and the opportunity in India is large enough to drive growth.
Pricing & Oversupply
- Base amines under structural pressure: Methylamine and ethylamine face significant overcapacity; plants are built for the long term, not short-term demand, so it will take a while for capacities to be absorbed domestically.
- Methylamine pressure is local, not imported: Methylamine cannot be transported long distances or exported, so pricing pressure is domestic; the impact comes from Chinese imports of agrochemical derivatives that use methylamine, creating upstream margin pressure on the base chemical.
- Ethylamine caught between stable pharma and sluggish agro: Pharma demand is stable while agrochemical demand has been up and down with only marginal increases over years; the company expanded capacity in FY23-24 and competitors also have existing capacity, creating an oversupplied situation in India.
- Acetonitrile pricing stable but at rock-bottom: Prices remain stable at a very low level with marginal differences of a few rupees; continued dumping from China keeps prices depressed.
- New competitor capacity will add to the glut: If a competitor's new ACN plant comes on stream, oversupply will impact profitability of all industry players; this is described as a normal market phenomenon when new capacities come on stream.
- Aarti Drugs backward integration tracked but not simple: Aarti Drugs backward integrating into methylamine is being watched; management noted methylamine production is not simple despite being a one-step reaction, and new capacity will add to oversupply and pressure margins; Aarti Drugs is not a significant customer but has decent demand.
Udipt Agarwal: "Yes, the major oversupply situation is in the amines, yes, which is the methylamine and ethylamines, base amines. And there is a significant over-capacity. But we also have to keep this in perspective that when we build these plants, these plants are built for long term."
Acetonitrile & Trade Policy
- Anti-dumping duty recommended, not yet imposed: DGTR has announced imposition of anti-dumping duty on acetonitrile originating from certain regions/countries; this is only a recommendation and the Ministry of Finance must approve it, typically within 90 to 100 days.
- Impact expected in H2 FY26: Management expects impact post imposition sometime in the second part of Q2 FY26; every time there would be an inventory impact, and the same conditions will apply to other Indian ACN producers.
- Realization upside uncertain: When asked if acetonitrile realization could increase 15-20% post anti-dumping duty, management said it is hard to say and declined to confirm the range.
- US tariffs could worsen China dumping into India: If China becomes less competitive in the US market, those capacities need to find a new home; management expects the intensity of dumping into India to increase, though this has not been seen yet and depends on what happens in the next couple of months in the US.
Udipt Agarwal: "The speculation, the theory is right, I mean, if China would be less and less competitive in U.S. market, all those capacities need to find a new home. And India, which has already been a dumping ground for the international producers, I expect the intensity to increase."
New Products & CAPEX
- Dahej project progressing on schedule: Mechanical completion expected by December 2025 or January 2026; products will be launched in the market post that, with some impact showing up in the next financial year.
- New products are specialty chemical focused: The new products are more on the specialty chemical side; as a policy, the company does not announce new products in advance and will announce when the product is ready and they start selling.
- Other pipeline projects in early stages: A few other projects are in the pipeline but timelines are not yet decided and amounts are still being finalized; the company will announce as and when ready.
- GLP drug demand for acetonitrile still early: Customers are talking about significantly higher volumes in this area, but management is still trying to assess whether the demand is really multiple times current levels; it is still early stages.
Udipt Agarwal: "As a policy, we do not announce it. So of course, some of the customers where we have tested it know about it. But as a policy, we do not announce it. When the product is ready and we start selling, we will be announcing it."
Margins & Profitability
- EBITDA margin stabilized at 20-21%: Margin has stabilized around this level, but pressure on prices continues to remain as in the past year; management does not foresee improvement at present because price pressure continues.
- Price pressure to persist through FY26: Methylamine and ethylamine pricing will continue to have a similar situation in FY26; it is too early to comment on how prices will move.
- Oversupply likely to last years: With massive overcapacity and new capacity coming from players like Aarti Drugs, the market is going to remain long in the next few years; it all depends on demand development.
Capital Allocation & Governance
- Promoter buying from open market: A promoter group project trading company is buying shares from the open market; when asked if this signals a market bottom, management declined to comment, saying it is difficult to say what the bottom level is.
- No buyback or shareholder reward planned: Management is not aware of any buyback or other form of reward for shareholders being considered.
- No PLI scheme for chemicals yet: No PLI scheme for chemical or specialty chemical industries exists as yet; it has been in the works for years but nothing concrete at this moment.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Volume growth | Double-digit growth around 10% to 15% | FY26 |
| Methylamine/ethylamine pricing | Similar pressured situation to continue | FY26 |
| Acetonitrile anti-dumping impact | Impact expected post imposition of duty | Second part of Q2 FY26 |
| Dahej CAPEX mechanical completion | Mechanical completion of new project | December 2025 or January 2026 |
| Dahej new product financial impact | Some impact to show up | Next financial year (FY27) |
| EBITDA margin improvement | Management does not foresee improvement at present | No timeline given |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Revenue growth | 9% YoY for FY25 |
| Volume growth (QoQ) | 4% to 5% |
| Volume growth (YoY) | ~15% |
| Volume growth (FY25) | ~13% |
| EBITDA margin | 21%, compared to ~19% last year |
| Revenue split: Amines | ~50% |
| Revenue split: Amine derivatives | ~30% |
| Revenue split: Specialty chemicals | ~18% to 20% |
| Exports share of total sales | ~20%, 20:80 ratio continued |
| Average capacity utilization | 60% to 70% across all plants |
| Acetonitrile current pricing | ₹140 to ₹150 |
| DGTR anti-dumping duty recommendation range | $205 to $480 per metric ton |
| CAPEX for new Dahej product | ₹110 crores to ₹120 crores |
| Total CAPEX forecast for next year | ~₹150 crores, including ~₹100 crores at Dahej |
| Volume growth expectation for next year | 10% to 15% |